The evolving role and utility of off-label drug use in multiple myeloma
The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 19 drug approvals and at least eight different active classes. The advances seen in MM therapy have rel...
Main Authors: | James H Stoeckle, Faith E Davies, Louis Williams, Eileen M Boyle, Gareth J Morgan |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration Publishing Inc.
2021-08-01
|
Series: | Exploration of Targeted Anti-tumor Therapy |
Subjects: | |
Online Access: | https://www.explorationpub.com/Journals/etat/Article/100250 |
Similar Items
-
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
by: Thumallapally N, et al.
Published: (2016-08-01) -
Carfilzomib boosted combination therapy for relapsed multiple myeloma
by: Steiner RE, et al.
Published: (2017-02-01) -
Off-label use of thalidomide for the treatment of a bleeding cutaneous metastasis
by: Federico Silvestri, et al.
Published: (2015-10-01) -
How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01) -
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
by: Offidani M, et al.
Published: (2021-06-01)